Key result
Physical exercise exerts cardioprotective effects during doxorubicin treatment and can attenuate acute and late-onset cardiotoxicity associated with this chemotherapy.
Why the study?
Doxorubicin is an effective first-line chemotherapy drug, but its clinical application is limited by potentially lethal dose-dependent cardiovascular toxicity.
Does exercise training prevent doxorubicin-induced cardiomyopathy in patients receiving doxorubicin chemotherapy?
Does exercise training prevent doxorubicin-induced cardiomyopathy in patients receiving doxorubicin chemotherapy?
This paper discusses the potential role of exercise training in preventing doxorubicin-induced cardiomyopathy.
Supports exercise during doxorubicin; hypothesis-generating and should not yet change practice.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Machado et al. (2022) conducted an editorial in Doxorubicin-induced cardiomyopathy. Exercise training was evaluated. Physical exercise exerts cardioprotective effects during doxorubicin treatment and can attenuate acute and late-onset cardiotoxicity associated with this chemotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: